Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | PCNA | P12004 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | IAPP | P10997 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716575 | 1.00 | ALOX5 (0.51) | ALOX5OR51E2APPHIF1APCNA | |
| SCHEMBL17594761 | 0.91 | MTNR1A (0.48) | ALOX5OR51E2HIF1APCNAPOLB | |
| SCHEMBL3274537 | 0.85 | APP (0.68) | ALOX5OR51E2APPHIF1AMAPK1 | |
| SCHEMBL14901973 | 0.84 | PTPN1 (0.43) | ALOX5OR51E2APPALDH1A1LMNA | |
| SCHEMBL4108699 | 0.83 | GAA (0.66) | HIF1APCNAPOLBTHRATHRB | |
| SCHEMBL1746736 | 0.83 | PCNA (0.44) | ALOX5OR51E2HIF1APCNAPOLB | |
| SCHEMBL2722450 | 0.83 | CA12 (0.43) | ALOX5OR51E2PTPN1 | |
| SCHEMBL2722156 | 0.83 | L3MBTL1 (0.43) | ALOX5OR51E2POLBMAPTPTPN1 | |
| SCHEMBL1446362 | 0.83 | ALOX5 (0.50) | ALOX5OR51E2PTPN1 | |
| SCHEMBL18269500 | 0.82 | ALOX5 (0.53) | ALOX5OR51E2APPALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103030646-B | Benzodioxane analog derivative, its preparation method and in application pharmaceutically | 上海恒瑞医药有限公司 | 2016-08-24 | — | — | CN | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| CN-103030646-A | Benzodioxane derivative, and preparation method thereof and application of derivative in medicines | SHANGHAI HENGRUI PHARM CO LTD | 2013-04-10 | — | — | CN | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-6586442-B2 | Benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | CARNIATO DENIS (FR) | 2003-07-01 | — | — | US | disclosed |
| US-20020187976-A1 | New benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2002-12-12 | — | — | US | disclosed |
| US-6458801-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS AND ITS PRODRUG USEFUL FOR TREATING OSTEOPOROSIS. | AVENTIS PHARMA S.A. (FR) | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187976-A1 | New benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | CYP2F1, CYP2C19, CYP2B6 | ALOX5 879/4885OR51E2 4003/4885APP 955/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | ALOX5 3500/4885OR51E2 381/4885APP 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.